Docket #: S25-120

Embryo-Guided Uterine Therapy to Boost IVF Implantation Success

Stanford researchers have identified a novel, embryo-informed strategy to improve the chances of pregnancy for patients undergoing in vitro fertilization (IVF). Instead of focusing only on systemic maternal hormones, this technology enhances local embryo-derived signals that help "tune" the uterine lining into a more welcoming environment for the implanting embryo.

Failed implantation remains one of the biggest barriers in IVF, despite high costs and carefully managed hormone regimens. Using advanced single-cell and spatial profiling, the inventors discovered that specific signals coming from the early embryo can transform endometrial stromal cells and reprogram local immune cells to support implantation rather than oppose it. These embryo-responsive stromal cells adopt a specialized, immunoregulatory state and help resolve inflammatory niches that would otherwise be hostile to implantation, thereby promoting a more permissive endometrial microenvironment around the time of embryo transfer.

Building on these insights, the inventors' technology enables targeted delivery of an embryo-mimetic signaling cue directly to the uterus — for example via intrauterine infusion, vaginal formulations, or drug-eluting devices — to complete decidualization and promote local immune tolerance during the implantation window. This embryo-informed adjunct is designed to integrate seamlessly with existing IVF protocols, with the goal of increasing implantation rates, reducing the number of cycles required, and lowering the emotional and financial burden on patients worldwide.

Stage of Development
Proof of concept – *in vitro* data

Applications

- Adjunct therapy to improve implantation, pregnancy, and live birth rates in IVF and related fertility treatments
- Targeted uterine immune modulation to reduce implantation failure and miscarriage in high risk patients (e.g., prior failed transfers or recurrent loss)
- Human model system for drug discovery and mechanistic studies of embryo–uterine interactions, decidualization, and local immune regulation

Advantages

- Embryo-centric mechanism leverages local, embryo-derived signaling to drive more physiological decidualization and localized immune tolerance
- Local intrauterine or vaginal administration focuses drug exposure at the implantation site, potentially minimizing systemic side effects
- Designed to plug into standard IVF workflows and hormone regimens, complementing rather than replacing current protocols and infrastructure

Innovators

- Andreas Lackner
- Robert Michael Angelo

Licensing Contact

Mona Wan

Senior Licensing Manager for Special Projects

Email